2523a. Group Leader
Session: Poster Discussion Round: Diagnostics
Saturday, October 6, 2018: 12:30 PM
Room: S Poster Hall
Charles Y. Chiu, M.D., Ph.D., Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA

Charles Chiu, M.D., Ph.D., currently heads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics, investigation of emerging pathogens, including Borrelia burgdorferi (Lyme disease), Ebola virus, enterovirus D68, and Zika virus, and clinical / public health applications of new diagnostic technologies such as nanopore sequencing. He is the principal investigator of the nationwide, multi-site “Precision Diagnosis of Acute Infectious Diseases” study (June 2016 – July 2017) to investigate the clinical impact and cost-effectiveness of a validated metagenomic next-generation sequencing assay for diagnosis of encephalitis and meningitis in hospitalized patients. His work is supported by funding from the National Institutes of Health (NIH), Abbott Laboratories, Department of Defense, NASA/Translational Research Institute philanthropic grants (Sandler, Bowes, and Schwab Foundations), and the California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 70 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Therabio, Inc.


Disclosures:

C. Y. Chiu, None

See more of: Diagnostics
See more of: Poster Discussion Round
Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.